### Pfizer Support to European and International Patient Organisations in 2016

#### Support to European organisations

The below list contains information on the support Pfizer has provided to European-level patient organisations in 2016, and services contracted from them (e.g. speaker fees), and to national and global patient organisations for European-level work. It follows the standards set out in the EFPIA code of practice governing relationships between the pharmaceutical industry and patient associations. Note that many of these declarations have also been declared in the country in which an organisation is based, dependent on local guidelines.

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Description</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer Europe</td>
<td>Alzheimer Europe is a non-governmental organisation aimed at raising awareness of all forms of dementia by creating a common European platform through co-ordination and co-operation between Alzheimer organizations throughout Europe. Alzheimer Europe is also a source of information on all aspects of dementia.</td>
<td>Pfizer Inc provided €20,000 to support Alzheimer Europe’s public affairs activities. This information is also declared on <a href="http://www.pfizer.be">www.pfizer.be</a>. Please be aware that the format may differ to follow Belgian transparency guidelines.</td>
</tr>
<tr>
<td>AntiCoagulation Europe (ACE)</td>
<td>ACE is a UK registered charity founded in the year 2000. ACE works with patients, healthcare professionals, NHS trusts, industry, governments, other charities and patient groups and a wide range of other organisations. Its aims are: the prevention of thrombosis; the provision of information, education and support; the promotion of independence - supporting people to take an active part in their own healthcare.</td>
<td>Pfizer Ltd on behalf of the BMS-Pfizer Alliance (an alliance between Bristol-Myers Squibb Pharmaceuticals Ltd and Pfizer Ltd) provided an independent speaker honorarium of £1,040 to ACE. This figure is the total of Pfizer’s contribution via the Pfizer-BMS alliance, and is 50% of the total paid. This information is also declared on <a href="http://www.pfizer.co.uk">www.pfizer.co.uk</a>. Please be aware that the format may differ to follow UK transparency guidelines.</td>
</tr>
<tr>
<td>L'Association Savoir Patient (ASAP)</td>
<td>The Knowledge Patient Association (ASAP) was founded in Geneva in 2003. It recognises the knowledge developed by people who daily confront their illness.</td>
<td>Pfizer Inc provided €35,000 to support GynCa Hub – a European ovarian cancer patient advocacy</td>
</tr>
</tbody>
</table>
Europa Donna

Organisation Description
Europa Donna, the European Breast Cancer Coalition, is an independent non-profit organisation founded in 1993, whose members are affiliated groups from countries across Europe. The Coalition works to raise awareness of breast cancer and to mobilise the support of European women in pressing for improved breast cancer education, appropriate screening, optimal treatment and care and increased funding for research. Europa Donna represents the interests of European women regarding breast cancer to local and national authorities, as well as to institutions of the EU. Europa Donna has 46 country members and its Head Office is located in Milan, Italy.

Funding

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>€50,000</td>
<td>Pfizer Inc provided a contribution to support Europa Donna’s annual work plan 2015.</td>
</tr>
<tr>
<td>€15,000</td>
<td>Pfizer Inc provided a contribution to support Europa Donna’s special project – website.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.it](http://www.pfizer.it). Please be aware that the format may differ to follow Italian transparency guidelines.

European Cancer Patient Coalition

Organisation Description
Established in 2003, the European Cancer Patient Coalition is the voice of the European cancer patient community, uniquely representing the interests of all cancer patient groups from the most common to the rarest forms of cancer.

Funding

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>€15,000</td>
<td>Pfizer Inc provided support for the Value of Innovation project in 2016.</td>
</tr>
<tr>
<td>€15,000</td>
<td>Pfizer Inc provided support for ECPC’s 2016 Annual General Meeting in Brussels.</td>
</tr>
<tr>
<td>€62,000</td>
<td>Pfizer Inc provided advanced support for the ECPC’s Immuno-Oncology Portal in 2017.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.

European Federation of Chrohn’s and Ulcerative Colitis Associations (EFCCA)

Organisation Description
EFCCA is a European umbrella organisation representing 33 national patients’ associations. EFCCA aims to work to improve life for people with IBD and give them a louder voice and higher visibility across Europe and beyond.

Funding

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>€8,500</td>
<td>Pfizer S.r.l. provided an educational grant for the EFCCA Network Communications platform.</td>
</tr>
<tr>
<td>€10,000</td>
<td>Pfizer S.r.l. provided an educational grant for the EFCCA Patient Safety education programme.</td>
</tr>
<tr>
<td>Amount</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
</tr>
<tr>
<td>€10,000</td>
<td>Pfizer S.r.l. provided an educational grant for translation of the European ECCO Guidelines project.</td>
</tr>
<tr>
<td>€10,000</td>
<td>Pfizer S.r.l. provided an educational grant for the EU stakeholder mapping project.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.

### European Federation of Neurological Associations (EFNA)

**Organisation Description**
The European Federation of Neurological Associations (EFNA) brings together European umbrella organisations of neurological patient advocacy groups, to work with other associations in the field of neurology, in what has been termed a ‘Partnership for Progress’. EFNA engages in activities, which contribute to the advancement of neurology and related areas with a view to improving the quality of life of people living with neurological conditions, their families and carers.

**Funding**
Pfizer Inc provided €50,000 to support EFNA’s “Under the Umbrella” communications campaign and MEP interest group meetings.

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.

### European Gaucher Alliance (EGA)

**Organisation Description**
The EGA is an umbrella organisation that supports and represents national Gaucher associations on a pan-European level. It has provided patient focused guidance, support and advice to industry, healthcare providers, governments, the EU, developing patient organisations, scientists and physicians and all other stakeholders in the Gaucher Community.

**Funding**
Pfizer Inc provided £49,500 as general operating support and to support the EGA 2016 strategic initiatives.

This information is also declared on [www.pfizer.co.uk](http://www.pfizer.co.uk). Please be aware that the format may differ to follow Belgian transparency guidelines.

### European Haemophilia Consortium (EHC)

**Organisation Description**
The European Haemophilia Consortium (EHC) is a European patient group representing national member organisations from 43 countries in Europe including members in all 28 Member States. The EHC is working to reduce the burden of the disease on both the individual and on society. Its mission is to improve the quality of life of people with Haemophilia in Europe.

**Funding**
Pfizer Inc provided €60,000 as sponsorship of the EHC workshop on economics and health technology assessment.
**European Institute of Women’s Health (EIWH)**

**Organisation Description**
Founded in 1996, The European Institute of Women’s Health (EIWH), is a non-governmental organisation based in Dublin established to promote gender equity in public health, research and social policies across Europe. The EIWH strives to make the health and well-being of women and the family, a priority for the European Commission and EU Member States.

**Funding**
Pfizer Inc provided EIWH with €15,550 to support the development of a policy brief on breast cancer.

---

**European Men’s Health Forum (EMHF)**

**Organisation Description**
The European Men’s Health Forum (EMHF) is the only European organisation dedicated to the improvement of men’s health in all its aspects, and a platform for the collaboration of a wide range of stakeholder groups in Europe. It aims to promote collaboration between interested individuals and organisations on the development and application of health policies, research, education and prevention programmes. In addition, EMHF strives to raise the profile of men’s health issues across Europe, develop Europe-wide policies and support the establishment and development of men’s health organisations that pursue similar objectives in each European country.

**Funding**
Pfizer Inc provided €37,000 to support the EMHF project to improve men's use of pharmacy services across Europe.

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.

---

**European Patients’ Forum (EPF)**

**Organisation Description**
The European Patients’ Forum (EPF) is the umbrella patients’ organisation at EU level. It brings together a broad range of leading European and national patients’ organisations in different disease areas. Representing over 150 million patients, the EPF is a key interlocutor with European institutions, and promotes patients’ rights, participation and involvement in EU healthcare developments.

**Funding**

<table>
<thead>
<tr>
<th>Amount</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>€40,000</td>
<td>Pfizer SA provided a grant to support EPF’s annual work programme.</td>
</tr>
<tr>
<td>€25,000</td>
<td>Pfizer Inc provided a grant support to EFF’s Capacity Building Programme (payment initiated by Pfizer in 2016, received by EPF in 2017).</td>
</tr>
<tr>
<td>€6,250</td>
<td>Pfizer Inc provided a healthcare charitable contribution for journal access for EUPATI fellows.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian & Luxembourghish transparency guidelines.
EURORDIS (European Organisation for Rare Diseases)

Organisation Description
EURORDIS is a patient-driven alliance of patient organisations and individuals active in the field of rare diseases. EURORDIS' mission is to build a strong pan-European community of patient organisations and people living with rare diseases, to be their voice at the European level, and - directly or indirectly - to fight against the impact of rare diseases on their lives.

Funding

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>€65,000</td>
<td>Pfizer Inc provided a grant for general operating support.</td>
</tr>
<tr>
<td>€25,000</td>
<td>Pfizer Inc provided a grant to support the EURORDIS Roundtable of Companies (ERTC) symposium.</td>
</tr>
<tr>
<td>€15,000</td>
<td>Pfizer Inc provided a grant to support international initiatives including Rare Disease International and Rare Barometer.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.fr](http://www.pfizer.fr). Please be aware that the format may differ to follow French transparency rules.

GAMIAN Europe

Organisation Description
GAMIAN Europe (Global Alliance of Mental Illness Advocacy Networks – Europe) is a pan-European patient-driven federation of organisations across Europe assisting people affected by mental illness. Its main objectives are: advocacy, information and education, anti-stigma and discrimination, patients’ rights, cooperation, partnerships and capacity building.

Funding
Pfizer Inc provided a €20,000 grant to support GAMIAN Europe’s mental health and sexual health study.

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.

International Diabetes Federation Europe (IDF-Europe)

Organisation Description
As the only European advocate for people with diabetes and their healthcare providers, the International Diabetes Federation European Region works together with its member associations and other diabetes stakeholders to enhance the lives of people with diabetes. Many IDF member associations are made up of people with diabetes and health care professionals. The mission of the International Diabetes Federation is to promote diabetes care, prevention and a cure worldwide.

Funding
Pfizer Ltd provided €27,000 as a membership fee to IDF-Europe.

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.

Lithuanian Cancer Patients Organization (POLA)
Organisation Description
The Lithuanian Cancer Patient Coalition (POLA) is an umbrella non-governmental organisation, uniting other non-governmental organisations that work in the cancer field in the Republic of Lithuania. Youth Cancer Europe (YCE) is a network of young cancer survivors (aged 18-35) from across Europe, who are collaborating to address unmet needs of young people with cancer.

Funding
Pfizer Inc provided €30,000 to Youth Cancer Europe for 2017 meeting sponsorship (POLA is the receiving entity for YCE).

Lung Cancer Europe (LuCE)

Organisation Description
Lung Cancer Europe is a non-governmental organisation which was established in 2013 to provide a voice for lung cancer patients and their families at a European level. Through its member organisations (which are lung cancer organisations with a patient focus), LuCE reflects patients’ and their carers’ and families’ unique and direct experience and expertise in healthcare. LuCE is based in Switzerland.

Funding
Pfizer GmbH provided €25,000 to LuCE as 2016 annual membership.

National Patients Organisation (NPO Bulgaria)

Organisation Description
The National Patients' Organization (NPO) is the largest union of patient organizations in Bulgaria, comprising more than 80 disease-specific member organizations. NPO is represented through its legally endorsed membership in all 28 regions in Bulgaria. Since its inception in 2010, NPO has been annually granted the status of a nationally representative patients’ organization by the Ministry of Healthcare. NPO’s vision for the future is a patient-centred healthcare system where the patients’ rights are developed and affirmed, and with equal access to high quality healthcare for all Bulgarian citizens.

Funding
Pfizer Ltd provided €10,000 as an educational grant to support the Regional PACT Conference in Sofia, September 2016

PHA Europe

Organisation Description
The mission of Pulmonary Hypertension Association (Europe) is to find ways to prevent and cure pulmonary hypertension, and to provide hope for the pulmonary hypertension community through support, education, advocacy and awareness.

Funding
Pfizer Inc provided $25,000 to help sustain PHA Europe’s capability building project, particularly in Eastern Europe, and their policy activities in Brussels.

Sarcoma Patients EuroNet (SPAEN)

Organisation Description
Established in 2009, Sarcoma Patients EuroNet e.V./Assoc. (SPAEN) is a collaborative association based in Germany, which brings together European advocacy and support groups working together with patients who have some of the rarest cancers. Acting in partnership with clinical experts, scientific researchers and other stakeholders SPAEN is working to improve the treatment and care of sarcoma patients in Europe through improving information and support, and by increasing the awareness of sarcoma in the medical landscape and amongst the general public.

**Funding**

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>€12,500</td>
<td>Pfizer Inc provided half of 2016 annual membership.</td>
</tr>
<tr>
<td>€12,500</td>
<td>Pfizer GmbH provided half of 2016 annual membership.</td>
</tr>
</tbody>
</table>

**Stroke Alliance for Europe (SAFE)**

**Organisation Description**
SAFE is a non-profit-making organisation that represents a range of patient groups from across Europe whose mutual goal is to drive stroke prevention up the European political agenda and prevent the incidence of stroke through education.

**Funding**

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>€24,327</td>
<td>Pfizer Ltd on behalf of the BMS-Pfizer Alliance (an alliance between Bristol-Myers Squibb Pharmaceuticals Ltd and Pfizer Ltd) provided sponsorship for The Burden of Stroke Report. This figure is the total of Pfizer’s contribution via the Pfizer-BMS Alliance, and is 50% of the total paid.</td>
</tr>
<tr>
<td>€1,040</td>
<td>Pfizer Ltd on behalf of the BMS-Pfizer Alliance (an alliance between Bristol-Myers Squibb Pharmaceuticals Ltd and Pfizer Ltd) provided an independent speaker honorarium to ACE. This figure is the total of Pfizer’s contribution via the Pfizer-BMS alliance, and is 50% of the total paid.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.
Support to global organisations based in Europe

The below list contains information on the support Pfizer has provided to global patient organisations in 2015 based in Europe.

<table>
<thead>
<tr>
<th>Organisation Name</th>
<th>Organisation Description</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>CML Advocates Network</td>
<td>The CML Advocates Network is a worldwide network of non-profit organisations supporting patients with Chronic Myeloid Leukaemia (CML) and their relatives. The network does this by sharing knowledge and best practice, running joint campaigns, and educating advocates how to build and grow patient organisations. The network is run by volunteers who are CML patients. The CML Advocates Network is formally hosted by the Leukaemia Patient Advocates Foundation, a global patient-led non-profit foundation registered in Switzerland.</td>
<td>Pfizer Inc provided €53,750 support for the 2017 CML Horizons meeting.</td>
</tr>
<tr>
<td>Confederation of Meningitis Organisations (COMO)</td>
<td>The Confederation of Meningitis Organisations Inc. (CoMO) is an international member organisation working to reduce the incidence and impact of meningitis worldwide.</td>
<td>$70,000 Pfizer Inc sponsored COMO's regional conferences in Florida, Brussels and Bangkok for member organisations.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>€40,000 Pfizer Inc made a donation towards the organisation's Life Course Immunisation meeting in Brussels in May 2016.</td>
</tr>
<tr>
<td>Global Lung Cancer Coalition</td>
<td>The GLCC is an umbrella organisation that supports lung cancer awareness and best practice sharing among patient groups internationally. The GLCC operates from the UK.</td>
<td>Pfizer Inc provided £30,000 as to support the annual work programme of GLCC.</td>
</tr>
<tr>
<td>International Alliance of Patients’ Organisations (IAPO)</td>
<td>IAPO is a unique global alliance representing patients of all nationalities across all disease areas and promoting patient-centred healthcare around the world.</td>
<td></td>
</tr>
</tbody>
</table>
Funding

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$50,000</td>
<td>Pfizer Inc provided funding as an annual industry partnership member.</td>
</tr>
<tr>
<td>£33,000</td>
<td>Pfizer Inc provided Congress Sponsorship.</td>
</tr>
</tbody>
</table>

This information is also declared on [www.pfizer.co.uk](http://www.pfizer.co.uk). Please be aware that the format may differ to follow UK transparency guidelines.

### International Brain Tumour Alliance

**Organisation Description**
The International Brain Tumour Alliance (IBTA) is a unique global network for brain tumour patient and carer groups around the world. We work alongside, and represent, members of our community - including researchers, scientists, clinicians, nurses and allied healthcare professionals - to engage in advocacy, to raise awareness and to share information.

**Funding**
Pfizer Inc provided £9,000 to support the IBTA annual work programme.

This information is also declared on [www.pfizer.co.uk](http://www.pfizer.co.uk). Please be aware that the format may differ to follow UK transparency guidelines.

### International Conference on Rare Diseases & Orphan Drugs (ICORD)

**Organisation Description**
ICORD is an International Society for all individuals actively involved in rare diseases and/or orphan drugs, including health care, research, academic, industry, patient organisations, regulatory authorities, health authorities, and public policy professionals. The mission of ICORD is to improve the welfare of patients with rare diseases and their families world-wide through better knowledge, research, care, information, education and awareness.

**Funding**
Pfizer Inc provided $6,500 as core funding to support activities related to the ICORD 2016 congress.

### International Federation of Psoriasis Organisations (IFPA)

**Organisation Description**
IFPA is a non-profit organization made up of psoriasis associations from around the world. IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the lives of people who live with psoriasis and psoriatic arthritis and explore the challenges psoriasis presents to the international psoriasis community. IFPA is based in Sweden.

**Funding**
Pfizer Inc provided €35,000 as core funding to support post-World Psoriasis Day activities.

### International Kidney Cancer Coalition (IKCC)

**Organisation Description**
IKCC is an independent and democratic network of patient support and advocacy organizations established with the mission of improving the quality of life of patients and their families living with kidney cancer. IKCC provides information, support and assistance to national kidney cancer stakeholders.

**Funding**
Pfizer Inc provided $50,000 as core funding to support annual activities.
organizations.

### Funding

<table>
<thead>
<tr>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$50,000</td>
<td>Pfizer Inc provided support to Kidney Cancer Awareness Day and advocacy strategic planning</td>
</tr>
<tr>
<td>$56,000</td>
<td>Pfizer Inc provided 2017 Annual Sustaining Partners Membership</td>
</tr>
</tbody>
</table>

### International Patient Organisation for Primary Immunodeficiencies (IPOPI)

**Organisation Description**

IPOPI is the association of national patient organisations dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiency (PID) patients worldwide. Established in 1992, IPOPI works as the global advocate for the PID patient community in cooperation with its national member organisations and key PID stakeholders.

**Funding**

Pfizer Inc provided €10,000 as core funding to support the general mission of IPOPI.

This information is also declared on [www.pfizer.be](http://www.pfizer.be). Please be aware that the format may differ to follow Belgian transparency guidelines.
Appendix: Funding to organisations engaged in some work with patients.

Pfizer provides funding to a number of organisations that are not patient organisations, but which have patient organisation membership or are otherwise relevant to patients. As such, they are listed here for the sake of transparency.

**European Alliance for Personalised Medicine (EAPM):** Founded in 2012, The European Alliance for Personalised Medicine (EAPM) brings together Europe’s leading healthcare experts, healthcare organisations and institutions, and patient advocates to improve patient care by accelerating the development, delivery and uptake of personalised healthcare including personalised medicine and diagnostics. EAPM is based in Belgium. In 2016, Pfizer Inc. paid €50,000 to cover annual membership fees for 2015 and 2016, and €25,000 to cover annual membership fees for 2017.

**European Brain Council (EBC):** The European Brain Council (EBC) is a coordinating council formed by European organisations in neurology, neurosurgery, psychiatry, basic brain research (neuroscience), as well as patient organisations and companies from within the pharma and biotech industries. It represents a vast network of patients, doctors and scientists, and these stakeholders along with its industrial partners make it eminently suited to work in close partnership with the European Parliament and Commission, national governments as well as other policy making bodies. EBC is based in Belgium. In 2015 Pfizer Ltd provided EBC with £20,000 as an annual membership fee.

**European Society for Medical Oncology (ESMO):** ESMO is the leading European professional organisation for medical oncology. Comprising more than 15,000 oncology professionals from over 130 countries, ESMO is the society of reference for oncology education and information. ESMO is based in Switzerland. In 2016, Pfizer Inc. provided €15,000 to support the Patient Advocacy Track at the 2016 ESMO Congress.

**The Portuguese League Against Cancer (LPCC):** The Portuguese Cancer League (Liga Portuguesa Contra o Cancro - LPCC) is a non-profit non-governmental organization. LPCC’s mission is to: 1) Support cancer patient and his family, 2) Primary Prevention, 3) Secondary Prevention, 4) Research and training in oncology. In 2016 Pfizer Ltd. provided €80,000 for the Royal Sponsor Package for the European Conference on Tobacco or Health (ECToH).

**World Stroke Organisation:** WSO is a non-profit medical association that works to raise awareness of prevention and treatment of stroke. It is based in Geneva. In 2016, Bristol-Myers Squibb Inc. on behalf of the BMS-Pfizer Alliance (an alliance between Bristol-Myers Squibb Pharmaceuticals Inc. and Pfizer Inc.) provided €80,000 to support the general mission of WSO.